Abstract:As one of the most frequent autoimmune diseases, Sjogren's syndrome (SS) is characterized by overactive lymphocytic infiltration in the exocrine glands, with ensuing dry mouth and dry eyes. Unfortunately, so far, there are no appropriate therapies without causing overall immunosuppression. Tetrahedral framework nucleic acids (tFNAs) were regarded as promising nanoscale materials whose immunomodulatory capabilities have already been verified. Herein, we reveal, for the first time, that tFNAs were utilized to treat SS in female nonobese diabetic (NOD) mice, the animal model used for SS. We proved a 250 nM tFNA treatment was successful in suppressing inflammation and stimulating saliva secretion in NOD mice. Specialised proteins for the secretory function and structure of acinar cells in submandibular glands (SMGs) were restored. It has been the permanent goal for SS treatment to establish immune tolerance and stop disease development. Surprisingly, tFNA treatment guided T cells toward regulatory T cells (Tregs), while suppressing T helper (Th) cell responses. Th cells include Th1, Th17, and follicular helper T (Tfh) cells. Tregs are highly significant in immune tolerance. Inducing Tregs is a promising approach to reestablish immune tolerance. Comparable results were also observed in B cell responses. Reductions in the percentage of germinal center (GC) B cells and plasma cells were detected, and a marked increase in the percentage of regulatory B cells (Bregs) was also noticed. The mechanisms of inducing Tregs may associated with cytokine changes. Changes of T cell subsets, especially changes of Tfh, may influence the differentiation of B cells accordingly. Collectively, our results demonstrated the immunomodulatory capacities of tFNAs once again, which may provide a novel, safe, and effective option for the treatment of SS and other autoimmune diseases.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsami.1c14861.Figure S1, AFM image of tFNAs; Figure S2, blood cytokine concentration at the end point of the experiment; Figure S3–S5, representative immunofluorescence images of SMGs; Figure S6–S7, representative flow cytometry pattern and quantitative analyses of CD4+ T cell subsets; Figure S8, quantitative analysis of Th2 in SMGs; Figures S9 and S10, representative flow cytometry pattern and quantitative analyses of B cell subsets; Figure S11, representative histological images of heart, liver, lung, and kidney (PDF)This article has not yet been cited by other publications.

Efficacy of BAFF inhibition and B-cell depletion in non-obese diabetic mice as a spontaneous model for Sjögrens disease

Effect of Nourishing Yin, Strengthening Qi and Activating Blood Decoction on Fas/FasL in Salivary Glands of NOD Mice with Sjogren's Syndrome and Their Mrna Expression

Single-Cell Transcriptomics Reveals a Pivotal Role of DOCK2 in Sjögren Disease

Altered characteristics of regulatory T cells in target tissues of Sjögren's syndrome in murine models

Tetrahedral Framework Nucleic Acids Reestablish Immune Tolerance and Restore Saliva Secretion in a Sjögren’s Syndrome Mouse Model

Regulatory T cells and IFN-γ-producing Th1 cells play a critical role in the pathogenesis of Sjögren's Syndrome

Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjögren's disease

Ly9 (CD229) Antibody Targeting Depletes Marginal Zone and Germinal Center B Cells in Lymphoid Tissues and Reduces Salivary Gland Inflammation in a Mouse Model of Sjögren's Syndrome

The Critical Biomarkers Identification of Insulin Signaling Involved in Initiating cAMP Signaling Mediated Salivary Secretion in Sjogren Syndrome: Transcriptome Sequencing in NOD Mice Model

Effect of Lymphotoxin Blockage on Different Stages of Sjogren's Syndrome in an Animal Model

Sialoadenitis Progression in Nonobese Diabetic Mice and Its Correlation with Expression of Apoptosis-Associated Proteins in Salivary Glands and Serum IgG Levels.

Low Dose Interleukin-2 Ameliorates Sjögren's Syndrome in a Murine Model

Low Dose Interleukin-2 Ameliorates Sjögren’s Syndrome in a Murine Model

Attenuation of the BTLA/HVEM Regulatory Network in the Circulation in Primary Sjögren’s Syndrome

The impact of alternate-day fasting on the salivary gland stem cell compartments in non-obese diabetic mice with newly established Sjögren's syndrome

Inhibition of Cathepsin S in Autoimmune CD25KO Mouse Improves Sjögren Disease-Like Lacrimal Gland Pathology

Syndecan-1 Plays a Role in the Pathogenesis of Sjögren's Disease by Inducing B-Cell Chemotaxis through CXCL13–Heparan Sulfate Interaction

Interaction of Human Salivary Gland Epithelial Cells with B Lymphocytes: Implications in the Pathogenesis of Sjögren’s Syndrome

Secreted factors from dental pulp stem cells improve Sjögren’s syndrome via regulatory T cell-mediated immunosuppression

B7-H4 Inhibits the Development of Primary Sjögren’s Syndrome by Regulating Treg Differentiation in NOD/Ltj Mice

[Sjögren's disease: From pathophysiology to treatment]